C Diff Drug Development

Clostridioides difficile infection (CDI) is an urgent public health threat with limited preventative options. In this work, we developed a messenger RNA (mRNA)-lipid nanoparticle (LNP) vaccine targeting C. difficile toxins and virulence factors. This multivalent vaccine elicited robust …

Nature Communications - Xinchen Lv and colleagues design pan-specific protein mini-binders that neutralize Clostridioides difficile toxin B (TcdB) and solve TcdB-binder complex structures via...

Toxins TcdA and TcdB are the main virulence factors of Clostridioides difficile, a leading cause of hospital-acquired diarrhea. Despite their importance, there is a significant knowledge gap of druggable targets for inhibiting toxin production. To address this, we screened non-antibiotic phytochemic …

Acurx reports ibezapolstat's positive microbiome effects and Anthrax activity

Clostridioides difficile, a gram-positive, toxin-producing, spore-forming anaerobe, is a major cause of antibiotic-associated diarrhoea. The bacterium's intrinsic drug resistance limits current treatment options to fidaxomicin and vancomycin for initial episodes, with anti-toxin B monoclonal antibod …

Clostridioides difficile, a gram-positive, toxin-producing, spore-forming anaerobe, is a major cause of antibiotic-associated diarrhoea. The bacterium's intrinsic drug resistance limits current treatment options to fidaxomicin and vancomycin for initial episodes, with anti-toxin B monoclonal antibod …

Acurx readies ibezapolstat for Phase 3 CDI trials

The Clostridium Difficile Infections market is expected to surge due to the disease s increasing prevalence and awareness during the forecast period Furthermore launching various multiple stage Clostridium Difficile Infections pipeline products will significantly revolutionize the Clostridium Difficile Infections market ...

Dr. Abiola Olaitan has received $150,000 from the Canadian Foundation for Innovation’s John R. Evans Leaders Fund (CFI-JELF).

Postbiotics' ability to inhibit bacterial growth, biofilm disruption, and toxin reduction makes them a promising adjunctive for CDI treatment and a good solution to pathogens' antibiotic resistance.

An experimental vaccine failed to prevent Clostridioides difficile infection in a phase 3 trial but successfully reduced the duration of symptoms, infections requiring medical attention and antibiotic treatments, researchers reported.

Crestone’s novel therapy, CRS3123, demonstrated 97% clinical cure rate in small phase 2 study.

Crestone Pharmaceuticals recently shared topline results from a phase 2 trial of its investigational drug treatment for Clostridioides difficile infection.

The small-molecule protein synthesis inhibitor CRS3121 met its primary endpoints, with high rates of clinical cure at day 12 and low rates of CDI recurrence.

Polyphenols have been reported to inhibit C. difficile growth and toxin production by several mechanisms in preclinical studies. However, more clinical studies are needed to investigate their safety in humans.

BOULDER, Colo.--(BUSINESS WIRE)--Sep 5, 2024--

CRS3123 is a novel, small molecule, antibiotic drug candidate that selectively inhibits 1 form of the bacterial methionyl-tRNA synthetase enzyme and is not affected by resistance to any existing classes of antibiotics.

Key Points

Polyphenols have been reported to inhibit C. difficile growth and toxin production by several mechanisms in preclinical studies. However, more clinical studies are needed to investigate their safety in humans.

Proactive's Tylah Tully breaks down 'Just the Facts' of Immuron Ltd (NASDAQ:IMRN, ASX:IMC)'s (Immuron Ltd (NASDAQ:IMRN, ASX:IMC)) lastest ASX announcement....

The potential role of nemonoxacin, which can be administered parenterally, for treating CDIs was evidenced through the in vitro, ex vivo, and mouse models.

our results showed that HXZQ can protect mice from CDAD-related death as effectively as vancomycin and the combination of vancomycin and HXZQ may give even better protection.

It's time to look at oral vaccines to prevent C. difficile infections, experts say

Three PF-06425090 doses were safe and well-tolerated. Although the primary endpoint was not met, PF-06425090 reduced symptom duration, CDI requiring medical attention, and CDI-directed antibiotic treatment, highlighting its potential to reduce CDI-associated healthcare burden. NCT03090191.

The Phase 3 CLOVER trial still showed safety and potential benefits by reducing C difficile infection duration, medical attention needs, and antibiotic use.

Nestlé aims to increase the global availability of Vowst, an FDA-approved therapy for preventing recurrent C difficile infection, while also seeking new opportunities for the product worldwide.

The vaccine didn't reduce C difficile infections in at-risk adults, but it did show the potential to reduce infection severity and limit need for medical attention.

Three PF-06425090 doses were safe and well-tolerated. Although the primary endpoint was not met, PF-06425090 reduced symptom duration, CDI requiring medical attention, and CDI-directed antibiotic treatment, highlighting its potential to reduce CDI-associated healthcare burden. NCT03090191.

The study is registered at ClinicalTrials.gov (NCT03931941).